Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.08), $0.04 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $29.8 million versus the consensus estimate of $23.82 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.